DIBENZYLINE (phenoxybenzamine hydrochloride) by Pfizer is clinical pharmacology phenoxybenzamine hydrochloride is a long-acting, adrenergic, alpha -receptor-blocking agent, which can produce and maintain "chemical sympathectomy" by oral administration. Approved for the treatment of pheochromocytoma, to control episodes of hypertension, sweating and 1 more indications. First approved in 1953.
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
Dibenzyline (phenoxybenzamine HCl) is a long-acting alpha-adrenergic receptor blocker approved in 1953 for treating pheochromocytoma and controlling hypertensive episodes, sweating, and associated symptoms. It works by producing 'chemical sympathectomy' through oral administration, increasing blood flow to skin and viscera while lowering blood pressure. The drug has a 24-hour IV half-life with cumulative effects over approximately one week of daily dosing.
As LOE approaches with limited recent commercial activity, opportunities exist in transition planning and legacy product management rather than growth-focused expansion.
CLINICAL PHARMACOLOGY Phenoxybenzamine hydrochloride is a long-acting, adrenergic, alpha -receptor-blocking agent, which can produce and maintain "chemical sympathectomy" by oral administration. It increases blood flow to the skin, mucosa and abdominal viscera, and lowers both supine and erect…
Worked on DIBENZYLINE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on Dibenzyline offers deep expertise in rare disease management, niche product lifecycle strategy, and specialized physician engagement—valuable skills for rare endocrine oncology career tracks. However, the product's mature, low-growth status and minimal linked job openings indicate limited hiring and advancement opportunities compared to growth-stage assets.